INSIDE HEALTH POLICY INTERVIEWS IACP ON OFFICE-USE COMPOUNDING
An international group of compounders is working with lawmakers to draft a new letter asking FDA to rescind guidance requiring a patient-specific prescription for each drug compounded under 503A, and to return to states control over office-use compounding, saying the agency’s prohibition on such compounding runs against congressional intent. The call to rescind the guidance …
INSIDE HEALTH POLICY INTERVIEWS IACP ON OFFICE-USE COMPOUNDING Read More »
